Phase II trial compares high-dose and standard amphotericin B for histoplasmosis, indicating feasibility for future trials.
Hierarchical composite endpoints may better reflect patients’ outcomes, rather than mortality alone. We applied DOOR and Win-Ratio analyses to a phase II trial comparing single high-dose versus standard liposomal amphotericin B for HIV-associated histoplasmosis. No clear differences were observed, supporting feasibility and informing design of future phase III trials.
No takes yet. Share an insight, caveat, or question.
Vieceli et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: